FIRM FIXED PRICE
NOVARTIS PHARMACEUTICALS CORPORATION - FABHALTA 200 MG
PIID: 36C24526N0323
Signed Date: Feb 12, 2026Effective Date: Feb 12, 2026End Date: Closed on Feb 23, 2026
Key Details
Description
FABHALTA 200 MG
Contractor Information
Contractor: NOVARTIS PHARMACEUTICALS CORPORATION
UEI: NG61ZA8TADW3
CAGE Code: 04520
Location: EAST HANOVER, NJ
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.